Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 3 | 4 |
| 2005 | 7 | 2 | 9 |
| 2006 | 5 | 8 | 13 |
| 2007 | 6 | 6 | 12 |
| 2008 | 7 | 7 | 14 |
| 2009 | 11 | 4 | 15 |
| 2010 | 17 | 15 | 32 |
| 2011 | 12 | 10 | 22 |
| 2012 | 22 | 8 | 30 |
| 2013 | 23 | 9 | 32 |
| 2014 | 16 | 9 | 25 |
| 2015 | 14 | 15 | 29 |
| 2016 | 16 | 11 | 27 |
| 2017 | 9 | 13 | 22 |
| 2018 | 11 | 10 | 21 |
| 2019 | 12 | 9 | 21 |
| 2020 | 5 | 11 | 16 |
| 2021 | 13 | 9 | 22 |
| 2022 | 2 | 12 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
-
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 Feb 10; 41(5):1129-1131.
-
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022 11 01; 107(11):2641-2649.
-
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Feb 10; 41(5):1105-1115.
-
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
-
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022 09 21; 43(36):3477-3489.
-
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force. Blood Adv. 2022 09 13; 6(17):5041-5044.
-
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 09; 17(9):1130-1136.
-
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 12; 20(6):510-514.
-
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. Am J Hematol. 2022 08; 97(8):E296-E298.